These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 22746405

  • 21. Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.
    Spreghini E, Maida CM, Milici ME, Scalise G, Barchiesi F.
    Antimicrob Agents Chemother; 2008 Feb; 52(2):513-7. PubMed ID: 18056279
    [Abstract] [Full Text] [Related]

  • 22. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
    O'Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ.
    J Antimicrob Chemother; 2006 Dec; 58(6):1168-76. PubMed ID: 17071635
    [Abstract] [Full Text] [Related]

  • 23. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S.
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [Abstract] [Full Text] [Related]

  • 24. Effects of calcineurin inhibitors, cyclosporine A and tacrolimus (FK506), on the activity of antifungal drugs against Candida spp.
    Şen Kaya S, Kiraz N, Bariş A, Turan D, Öz Y, Dağ İ, Aygün G.
    J Med Microbiol; 2021 Apr; 70(4):. PubMed ID: 33915075
    [Abstract] [Full Text] [Related]

  • 25. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY, Xu YC, Shi Y, Lü HX, Liu Y, Zhao WS, Chen DM, Xi LY, Zhou X, Wang H, Guo LN.
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis.
    Schemuth H, Dittmer S, Lackner M, Sedlacek L, Hamprecht A, Steinmann E, Buer J, Rath PM, Steinmann J.
    Mycoses; 2013 May; 56(3):297-303. PubMed ID: 23170818
    [Abstract] [Full Text] [Related]

  • 29. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, Chandenier J, Chauveau V, Couprie B, Datry A, Feuilhade M, Grillot R, Guiguen C, Lavarde V, Letscher V, Linas MD, Michel A, Morin O, Paugam A, Piens MA, Raberin H, Tissot E, Toubas D, Wade A.
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [Abstract] [Full Text] [Related]

  • 30. Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A.
    Shinde RB, Chauhan NM, Raut JS, Karuppayil SM.
    Ann Clin Microbiol Antimicrob; 2012 Oct 04; 11():27. PubMed ID: 23035934
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.
    Nagappan V, Boikov D, Vazquez JA.
    Antimicrob Agents Chemother; 2010 Jan 04; 54(1):522-5. PubMed ID: 19841143
    [Abstract] [Full Text] [Related]

  • 33. Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.
    Li Y, Nguyen MH, Derendorf H, Cheng S, Clancy CJ.
    Antimicrob Agents Chemother; 2007 Aug 04; 51(8):2985-7. PubMed ID: 17517840
    [Abstract] [Full Text] [Related]

  • 34. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
    Meletiadis J, Stergiopoulou T, O'Shaughnessy EM, Peter J, Walsh TJ.
    Antimicrob Agents Chemother; 2007 Jun 04; 51(6):2053-64. PubMed ID: 17387150
    [Abstract] [Full Text] [Related]

  • 35. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets.
    Carrillo-Muñoz AJ, Quindós G, del Valle O, Santos P, Giusiano G, Ezkurra PA, Estivill MD, Casals JB.
    Chemotherapy; 2008 Jun 04; 54(1):38-42. PubMed ID: 18073469
    [Abstract] [Full Text] [Related]

  • 36. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans.
    Manavathu EK, Ramesh MS, Baskaran I, Ganesan LT, Chandrasekar PH.
    J Antimicrob Chemother; 2004 Feb 04; 53(2):386-9. PubMed ID: 14729762
    [Abstract] [Full Text] [Related]

  • 37. Post-antifungal effects and time-kill studies of anidulafungin, caspofungin, and micafungin against Candida glabrata and Candida parapsilosis.
    Smith RP, Baltch A, Bopp LH, Ritz WJ, Michelsen PP.
    Diagn Microbiol Infect Dis; 2011 Oct 04; 71(2):131-8. PubMed ID: 21865002
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.